Breast cancer diagnosed during pregnancy is a challenging clinical situation. Little data are currently available about chemotherapy in pregnant women with this malignancy. CASE REPORT: We report the case of a 36-year-old pregnant woman with a T2N1M0 breast cancer who received sequential chemotherapy including epirubicin (120 mg/m2 every three weeks for four cycles) and paclitaxel (175 mg/m2 every three weeks for three cycles) from the 14th to the 32nd week of gestation. The patient delivered a normal female baby by caesarean section at the 36th week. The immunohistochemical examination of the placenta showed a diffuse, strong P-glycoprotein expression. Thirty-six months after the delivery, the mother was disease-free and the infant showed normal development and growth. DISCUSSION: Sequential chemotherapy including epirubicin and paclitaxel should be taken into consideration as adjuvant treatment for pregnant women with high-risk breast cancer. The strong placental expression of P-glycoprotein may play a major role in limiting fetal exposure to anthracyclines and taxanes.

Chemotherapy with epirubucin and paclitaxel for breast cancer during pregnancy: case report and review of the literature / Gadducci, A; Cosio, S; Fanucchi, A; Nardini, V; Roncella, M; Conte, Pierfranco; Genazzani, A. R.. - In: ANTICANCER RESEARCH. - ISSN 0250-7005. - STAMPA. - 23:(2003), pp. 5225-5229.

Chemotherapy with epirubucin and paclitaxel for breast cancer during pregnancy: case report and review of the literature.

CONTE, Pierfranco;
2003

Abstract

Breast cancer diagnosed during pregnancy is a challenging clinical situation. Little data are currently available about chemotherapy in pregnant women with this malignancy. CASE REPORT: We report the case of a 36-year-old pregnant woman with a T2N1M0 breast cancer who received sequential chemotherapy including epirubicin (120 mg/m2 every three weeks for four cycles) and paclitaxel (175 mg/m2 every three weeks for three cycles) from the 14th to the 32nd week of gestation. The patient delivered a normal female baby by caesarean section at the 36th week. The immunohistochemical examination of the placenta showed a diffuse, strong P-glycoprotein expression. Thirty-six months after the delivery, the mother was disease-free and the infant showed normal development and growth. DISCUSSION: Sequential chemotherapy including epirubicin and paclitaxel should be taken into consideration as adjuvant treatment for pregnant women with high-risk breast cancer. The strong placental expression of P-glycoprotein may play a major role in limiting fetal exposure to anthracyclines and taxanes.
2003
23
5225
5229
Chemotherapy with epirubucin and paclitaxel for breast cancer during pregnancy: case report and review of the literature / Gadducci, A; Cosio, S; Fanucchi, A; Nardini, V; Roncella, M; Conte, Pierfranco; Genazzani, A. R.. - In: ANTICANCER RESEARCH. - ISSN 0250-7005. - STAMPA. - 23:(2003), pp. 5225-5229.
Gadducci, A; Cosio, S; Fanucchi, A; Nardini, V; Roncella, M; Conte, Pierfranco; Genazzani, A. R.
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/615360
Citazioni
  • ???jsp.display-item.citation.pmc??? 10
  • Scopus 72
  • ???jsp.display-item.citation.isi??? 52
social impact